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Abstract
Background: The cytokine leukemia inhibitory factor (LIF) mediates its biological effects through
binding to its high affinity receptor made of the low-affinity LIF receptor subunit gp190 (LIF-R) and
the gp130 subunit. LIF exerts several important effects in the liver, however, data on liver
expression of LIF are scarce. The aim of this study was to examine the expression of LIF and LIF-
R in human liver.
Results: LIF expression, analyzed by immunohistochemistry, was barely detectable in normal liver
but was strong within cirrhotic fibrous septa and was found in spindle-shaped cells compatible with
myofibroblasts. Accordingly, cultured human liver myofibroblasts expressed high levels of LIF as
shown by ELISA and Northern blot. Biological assay demonstrated that myofibroblast-derived LIF
was fully active. RT-PCR showed expression of the LIF-D and M isoforms, and also of low levels of
new variants of LIF-D and LIF-M resulting from deletion of exon 2 through alternative splicing. LIF
receptor expression was detected mainly as a continuous sinusoidal staining that was enhanced in
cirrhotic liver, suggestive of endothelial cell and/or hepatocyte labeling. Immunohistochemistry,
flow cytometry and STAT-3 phosphorylation assays did not provide evidence for LIF receptor
expression by myofibroblasts themselves. LIF secretion by cultured myofibroblasts was down
regulated by the addition of interleukin-4.
Conclusions: We show for the first time the expression of LIF in human liver myofibroblasts, as
well as of two new isoforms of LIF mRNA. Expression of LIF by myofibroblasts and of its receptor
by adjacent cells suggests a potential LIF paracrine loop in human liver that may play a role in the
regulation of intra-hepatic inflammation.
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Background
Leukemia inhibitory factor (LIF) belongs to the inter-
leukin (IL)-6 family of cytokines, together with IL-11, cil-
iary neurotrophic factor, cardiotrophin-1, oncostatin M
and neurotrophin-1/B cell stimulating factor-3. LIF is
widely expressed in tissues and in many isolated cells. LIF
expression is commonly up-regulated during inflamma-
tion. Nevertheless, its role seems to be complex as both
pro- and anti-inflammatory properties have been
described for that cytokine. Although LIF, like IL-6, is able
to drive a significant acute-phase reaction in non-human
primates [1], this has been questioned in humans [2]. LIF
exerts its biological activities through its binding to a het-
ero-oligomeric receptor complex between the low-affinity
LIF receptor subunit gp190 and the signal-transducing
subunit gp130. The gp130 subunit is common to all
members of the IL-6 family.
Several isoforms of LIF consecutive to alternative splicing
have been described. The second and third exons are com-
mon to all isoforms, whereas there are 3 alternate first
exons – D, M, and T. The fate of the mature LIF molecule
is highly dependent on exon 1 usage; thus, the human LIF-
D transcript encodes a secreted protein that is biologically
active and can signalize via the LIF receptor. The human
LIF-M transcript does not contain any in-frame AUG, but
it is known to be translated into both secreted and intrac-
ellular proteins [3]. The secreted LIF-M protein can also be
found sequestered in the extracellular matrix where it is
biologically active [4]. Finally, the first exon from the
human LIF-T, which does not contain any in-frame AUG,
is responsible for the synthesis of an intracellular protein
with a leucine zipper motif that might function as a tran-
scription factor [5].
As outlined above, LIF is potentially involved in liver
physiology and pathophysiology; however, data on liver
expression of LIF are scarce. LIF expression was not
detected in normal rat liver but it was highly induced fol-
lowing partial hepatectomy, mainly in non- parenchymal
cells [6], suggesting its involvement in liver regeneration.
To our knowledge, the expression of LIF has not been
described in human liver.
Therefore, the aim of this study was to examine the expres-
sion of LIF and of its specific receptor gp190 in human
liver. Results obtained with immunostaining of liver sec-
tions led us to examine LIF expression by cultured liver
myofibroblasts, cells that play a major role in liver
fibrogenesis.
Results
LIF expression
Human liver tissues were examined for LIF expression by
immunohistochemistry. In normal liver, a faint but con-
sistent LIF expression was detected in the stroma of portal
tracts (Fig. 1A). No signal was observed along sinusoids.
In fibrotic liver tissues, an intense expression of LIF was
seen along fibrous septa which is consistent with the pres-
ence of myofibroblasts (Fig. 1B). Staining adjacent sec-
tions with LIF antibody and with an antibody to alpha-
smooth muscle actin (that labels myofibroblasts) sug-
gested a large degree of colocalization (Figs. 1C,1D). Part
of the LIF staining also appeared to be extracellular. There
was no difference in the type of staining whatever the eti-
ology of liver fibrosis. No labeling was found when the
LIF antibody was replaced by a species-matched control
antibody.
Analysis of total RNA from cultured human liver myofi-
broblasts by Northern blot revealed a single 4.5 kb tran-
script (Fig. 2A). RT-PCR experiments, described in more
detail later, demonstrated the expression of both D and M
isoforms of LIF (Fig. 2B). When cell supernatants were
tested with an ELISA assay specific for human LIF, levels
ranged between 800 and 8 000 ng/ml in different isolates.
In order to make sure that this corresponded to biologi-
cally active LIF, the supernatants were tested for their abil-
ity to promote the growth of the LIF-dependent cell line
BaF3, stably transfected with the human gp190 and gp130
isoforms. As shown in Fig. 3, myofibroblasts supernatants
Immunohistochemical analysis of LIF expression in normal  and cirrhotic human liver Figure 1
Immunohistochemical analysis of LIF expression in 
normal and cirrhotic human liver. (a): LIF expression is 
seen in normal liver in the stroma of portal tracts (arrows); 
(b): LIF is strongly expressed in fibrotic septa in cirrhotic 
liver (arrows); (c) and (d): consecutive sections of a cirrhotic 
liver analyzed for LIF (c) or alpha-smooth muscle actin (d) 
expression. No labeling was seen when the antibodies were 
replaced by a species-matched control antibody.Comparative Hepatology 2004, 3:10 http://www.comparative-hepatology.com/content/3/1/10
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efficiently stimulated the growth of these cells in a dose-
dependent fashion, confirming that biologically active LIF
was effectively produced. Furthermore, the effect on BaF3
transfectants growth was abolished in the presence of the
blocking gp190 LIF receptor antibody 12D3. The results
of the ELISA combined with the 100 fold inhibition of
biological activity, seen after anti-gp190 addition, further
confirmed that most of the BaF3 growth-promoting activ-
ity produced by cultured myofibroblasts is likely to be LIF.
As shown in Figure 4, when cells were incubated with
graduated amount of recombinant human IL-4, the con-
stitutive LIF secretion was dose-dependently reduced,
demonstrating that this production may be regulated in
vivo.
Cloning of new isoforms of LIF mRNA
In order to test whether myofibroblasts transcribed all the
alternatively spliced D, M or T first exons, a first set of RT-
PCR experiments was carried out using the forward prim-
ers chosen in the alternative D, M or T first exons (hLIF-
D3, hLIF-M3 and hLIF-T5), and a common reverse primer
chosen in exon 3 (hLIF-N4) (Table 1 and Fig. 5). As shown
in Fig. 2B, PCR with D- or M-specific primers was positive.
Moreover, it always yielded a second, shorter, PCR prod-
uct in addition to the expected amplified product (Fig.
2B). Similar results were obtained with other primer sets
specific for either LIF-D (hLIF-D) or LIF-M (h-LIFM5)
combined with hLIF-3N (data not shown), which
strengthened the previous observation. No amplification
products were obtained with the T primer. Then, we
designed a reverse primer within exon 2 (hLIF-2N) that
was used in conjunction with the forward hLIF-D and
hLIF-M2 primers. In that case, we detected only a product
of the expected size for both D and M PCRs (not shown).
The sizes of the additional products obtained with the
hLIF-N4 primer were shorter by about 200 bp, which is
the exact size of exon 2, raising therefore the possibility
that the shorter PCR products were derived from a hith-
erto not described mRNA species where exon 2 was
deleted through alternative splicing. In order to investi-
gate this possibility, the short D and M fragments were
cloned into a plasmid and sequenced. Sequencing indeed
revealed that the first exon (either D or M) was directly
spliced to the third one resulting in new, short transcripts
that we have designated s-LIF-D and s-LIF-M.
The existence of these alternate transcripts could be
observed in several hepatocellular carcinoma cell lines
(HepG2, HuH7, Hep3B) and in the HEK293 cell line,
derived from embryonic human kidney (Fig. 6A). They
were also expressed in normal human liver samples (Fig.
6B) as well as in cirrhotic ones (Fig. 6C).
The relative abundance of the variant transcripts relative
to the classical transcripts was studied using a semi-quan-
titative RT-PCR method, where PCR was carried out for
Detection of LIF transcripts in cultured human liver  myofibroblasts Figure 2
Detection of LIF transcripts in cultured human liver 
myofibroblasts. (A): Northern blot. Total RNA from cul-
tured human liver myofibroblasts was hybridized with a 
cDNA probe to human LIF. A single 4.5 kb band was 
observed; (B) and (C): RT-PCR. Total RNA was subjected to 
reverse transcription then to PCR with the hLIF-D3/hLIF-N4 
(B) or with the hLIF-M3/hLIF-N4 primers (C).
Biological activity of myofibroblast-derived LIF Figure 3
Biological activity of myofibroblast-derived LIF. BaF3 
cells stably transfected with the gp130 and the gp190 subu-
nits were exposed to dilutions of recombinant human LIF 
(starting concentration: 4 ng/ml) (open circles), culture 
medium (filled squares), myofibroblast conditioned medium 
alone (filled circles) or together with the blocking anti-gp190 
antibody 12D3 at 20 µg/ml (filled triangles). Cell growth was 
monitored with a colorimetric assay. The figure shows the 
mean ± SD of 3 experiments performed in duplicate (SD are 
not always visible due to their small size).
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varying cycles numbers. As can be seen in Fig. 6D, expres-
sion of the s-LIF-D transcript lagged several cycles behind
that of the long transcript. Similar results were obtained
with the s-LIF-M transcript (not shown).
LIF receptor expression
The expression of the gp190 subunit by liver cells was
then examined by immunohistochemistry. Five different
antibodies, directed against separate epitopes, were used
and yielded similar results. In normal liver tissue, LIF
receptor (LIF-R) expression was detected as a continuous
sinusoidal staining and in the stroma of portal tracts (Fig.
7A). In the cirrhotic liver, the sinusoidal staining was
enhanced, whereas a very faint staining was observed in
fibrous septa (Fig. 7B). Staining adjacent sections with LIF
receptor antibody and with an antibody to CD31
(endothelial cells in the cirrhotic liver were labeled)
showed a large degree of colocalization (Figs 7C,7D).
In a subsequent step, cultured human liver myofibrob-
lasts were examined for their membrane expression of
gp190 using flow cytometry. Adherent cells were released
by action of EDTA and subjected to anti-gp190 labeling.
No detectable levels of gp190 were observed with any of
the 5 antibodies, although gp130 expression could be
detected with the B-R3 antibody. In order to detect a low-
level expression of functional LIF-R, myofibroblasts were
exposed for 15 minutes to 10 ng/ml recombinant LIF;
then, STAT-3 phosphorylation was examined by Western
blot. No consistent effects were seen in 7 separate experi-
ments. When a very weak signal was occasionally seen, it
was not inhibited by 2 separate blocking antibodies to
LIF-R (data not shown). Finally, production of soluble
receptor was never detected in myofibroblast superna-
tants either.
Discussion
In this study, we demonstrate for the first time that LIF is
expressed at low levels in normal human liver, whereas it
is greatly increased in fibrotic liver, in a localization
consistent with that of activated myofibroblasts. The
slightly diffuse staining is suggestive of extracellular
matrix deposition consistent with the expression of the M-
type isoform of LIF. Experiments using cultured human
liver myofibroblasts confirmed that these cells secreted
extremely high levels of LIF in the range of 0.1–1 µg/106
Table 1: Primers used for PCR
Primer Sequence (*): 5'> 3' Orientation Ref.
hLIF-D ATAATGAAGGTCTTGGCGGCAG Forward
HLIF-D3 AAACTGCAGGCATCTGAGGTTTCCTCCAA Forward
hLIF-M2 CTGGAAGCGTGTGGTCTG Forward
HLIF-M3 AAACTGCAGCTGGAAGCGTGTGGTCTG Forward
hLIF-M5 TAGAATTCTGGAAGCGTGTGGTG Forward [3]
hLIF-T5 ATGAATTCTGTCACCTTTCACTTTCCT Forward [3]
hLIF-2N AATAAAGAGGGCATTGGCAC Reverse
hLIF-3N TTCTGGTCCCGGGTGATGTT Reverse [3]
HLIF-N4 GCTCTAGAGAAGGCCTGGGCCAACAC Reverse
(*) Bases in italics refer to restriction sites.
Regulation of LIF secretion by interleukin-4 Figure 4
Regulation of LIF secretion by interleukin-4. Confluent 
cultures of human liver myofibroblasts were cultured in the 
presence of the indicated concentrations of IL-4, for 48 h in 
serum-free medium. LIF was measured by ELISA in the 
supernatant and the results were normalized according to 
the DNA content of the monolayer (mean ± SD of 3 experi-
ments). The effect of IL-4 was highly significant, as assessed 
by ANOVA (p = 0.001).
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cells/48 h. These levels are similar to those produced by
activated lymphocytes, a classic source of LIF, and suggest
that liver myofibroblasts may be a major source of LIF
during chronic liver diseases. Our results are in agreement
with data obtained in the rat showing that non-parenchy-
mal cells, possibly activated stellate cells (i.e.,
myofibroblasts), express LIF [6]. Another study also
reported an increased expression of LIF in peri-ductular
cells, following bile duct ligation in IL-6 knock-out mice
[7]; this location likely qualifies those cells as myofibrob-
lasts. LIF expression by liver myofibroblasts is also remi-
niscent of its expression by kidney mesangial cells, a close
relative to liver myofibroblasts, that we have previously
reported [8].
On the other hand, and in contrast with mesangial cells
[9], liver myofibroblasts do not appear to express cell sur-
face LIF-specific gp190 receptor subunit. This is based on
results obtained from immunohistochemistry, flow
cytometry, as well as functional experiments. This indi-
cates that LIF cannot exert an autocrine effect on liver
myofibroblasts. However, we show that myofibroblasts
express the IL-6 family common transducing subunit
gp130. In this regard, others have shown that human liver
myofibroblasts are responsive to oncostatin-M [10],
indicating the presence of its functional alternative recep-
tor consisting of gp130 and the specific OSMRβ chain.
Nonetheless, LIF receptor expression was detected by
immunohistochemistry in human liver, in a peri-sinusoi-
dal location. Similar results were obtained with 5 different
antibodies directed to several epitopes of gp190. The pat-
tern of continuous sinusoidal staining and the colocaliza-
tion experiments are in favor of an expression in
Sequence of LIF-D, M and T isoforms Figure 5
Sequence of LIF-D, M and T isoforms. Exons D, M and T are the 3 alternate first exons. Primers used for PCR are under-
lined. Primers hLIF-M2, M3 and M5 cover the same sequence but differ because of the presence or the absence of restriction 
sites.
h-LIF-T5
Exon D : ccggcatctgaggtttcctccaaggccctctgaagtgcagcccataatgaaggtcttggcggcag
h-LIF-D h-LIF-D3
Exon T : cacctttcactttccttcctccccgcccacccacctgcctatgaccttttgccttttctctctccatttcctctccctccctga
Exon M : ctggaagcgtgtggtctgcgctag 
h-LIF-M2, M3, M5 
Exon 2 : 
gagttgtgcccctgctgttggttctgcactggaaacatggggcggggagccccctccccatcacccctgtcaacgccacctgtgccata
cgccacccatgtcacaacaacctcatgaaccagatcaggagccaactggcacagctcaatggcagtgccaatgccctctttattctctat
h-LIF-2N
Exon 3 :
tacacagcccagggggagccgttccccaacaacctggacaagctatgtggccccaacgtgacggacttcccgcccttccacgccaac
ggcacggagaaggccaagctggtggagctgtaccgcatagtcgtgtaccttggcacctccctgggcaacatcacccgggaccagaa
gatcctcaaccccagtgccctcagcctccacagcaagctcaacgccaccgccgacatcctgcgaggcctccttagcaacgtgctgtgc
cgcctgtgcagcaagtaccacgtgggccatgtggacgtgacctacggccctgacacctcgggtaaggatgtcttccagaagaagaag
ctgggctgtcaactcctggggaagtataagcagatcatcgccgtgttggcccaggccttctagcaggaggtcttgaagtgtgctgtgaa
ccgag//             hLIF-N4Comparative Hepatology 2004, 3:10 http://www.comparative-hepatology.com/content/3/1/10
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RT-PCR analysis of LIF-M expression in various cell lines and in human liver Figure 6
RT-PCR analysis of LIF-M expression in various cell lines and in human liver. (A): LIF-M expression was analyzed 
with the hLIF-M2 and hLIF-3N primers: Line 1, human liver myofibroblasts; Line 2, HepG2; Line 3, Hep3B; Line 4, HuH7; Line 
5, HEK293. Product sizes are shown in bp; (B): normal human liver samples. LIF-D expression was analyzed with the hLIF-D3 
and hLIF-N4 primers in 4 different samples. The same samples also expressed LIF-M (not shown). Product sizes are shown in 
bp; (C): diseased human liver samples. In that case, LIF-M expression was analyzed with the hLIF-M3 and hLIF-4N primers in 4 
cases of cirrhotic liver. The same samples also expressed LIF-D (not shown). Product sizes are shown in bp; (D): semi-quanti-
tation of LIF-D and s-LIF-D expression in a human liver myofibroblasts sample. LIF-D expression was analyzed with the hLIF-
D3 and hLIF-N4 primers. The left part shows the migration pattern of the PCR-amplified products with the number of cycles 
above and the size of the products indicated by arrows, in bp. The graph on the right shows the signal quantification. Similar 
results were obtained with LIF-M.Comparative Hepatology 2004, 3:10 http://www.comparative-hepatology.com/content/3/1/10
Page 7 of 10
(page number not for citation purposes)
sinusoidal endothelial cells. However, we can not exclude
staining of the sinusoidal domain of hepatocytes. In any
case, these data indicate that cells close to LIF-producing
myofibroblasts express LIF receptors and could thus
respond to LIF in a paracrine fashion.
This study led to the discovery of new LIF transcripts
resulting from a direct splicing of exon 1 to exon 3. This
was observed for both LIF-D and LIF-M. Those transcripts
were present at much lower levels than full-length tran-
scripts, as suggested by RT-PCR and by the fact that they
do not appear on Northern blot; thus, their biological
relevance can be questioned. Whether s-LIF-D or s-LIF-M
transcripts are translated also remains hypothetical. In the
case of s-LIF-D, initiation at the AUG within exon D
would result in a reading-frame shift following the 6th
amino-acid (aa) and a termination at aa 88, the resulting
protein bearing no homology with LIF. There are,
however, several in-frame CUG codons within exon 3. Ini-
tiation at CUG 113 would result in the synthesis of a 125
aa polypeptide, recapitulating the sequence of the C-ter-
minal part of LIF. Similar considerations apply to s-LIF-M
that, in any case, does not contain an initiating AUG in
exon 1. It should be emphasized that the lack of an AUG
codon does not preclude the translation of the classical
forms of LIF-M or LIF-T [3,5]. More experiments are
needed to know whether these new transcripts are
translated.
LIF secretion was dose-dependently decreased by IL-4, a
known inhibitor of LIF secretion in other cell types
[11,12]. IL-4 is also known to up-regulate collagen synthe-
sis in human liver myofibroblasts and could thus be a pro-
fibrogenic mediator in the liver [13]. Whether LIF expres-
sion is relevant to liver fibrogenesis needs to be assessed.
LIF could affect extracellular matrix remodeling since it
regulates the expression of several matrix proteinases and
their inhibitors in various cell types [14,15]. In addition,
LIF could play a role in the pathophysiology of chronic
liver diseases through action on endothelial cells and on
hepatocytes. Regarding endothelial cells, and depending
on the model, both pro-angiogenic [16] and anti-ang-
iogenic effects [17] have been described. Especially inter-
esting is the demonstration that LIF can stimulate the
adhesion of neutrophils to endothelial cells [18]; indeed,
neutrophils are involved in the pathogenesis of liver dis-
eases such as alcoholic liver disease. As already men-
tioned, the effects of LIF on human hepatocytes are still
being debated [2].
Conclusions
For the first time, we show the expression of LIF in human
liver myofibroblasts, as well as of two new isoforms of
mRNA. Hepatic stellate cells and activated myofibroblasts
have already been shown to synthesize a number of medi-
ators involved in the control of inflammation, such as
monocyte chemotactic-1 protein [19], or platelet-activat-
ing factor [20]. Expression of LIF by myofibroblasts and of
its receptor by adjacent cells suggest a potential LIF
paracrine loop in human liver that may play a role in the
regulation of intra-hepatic inflammation and reinforces
the concept of a major role of liver myofibroblasts in the
regulation of intra-hepatic inflammation [21].
Methods
Tissue samples
Histologically normal/subnormal liver samples were
obtained from macroscopically normal location in hepa-
tectomy specimens, taken at a distance from a focal nod-
ular hyperplasia (n = 5); a hemangioma (n = 1); or a colon
cancer metastasis (n = 1). Cirrhotic specimens (n = 11)
were obtained from patients undergoing liver transplanta-
tion for cirrhosis with associated hepatocellular carci-
noma. In 10 out of 11 cases, the patients underwent liver
transplantation. The cirrhosis etiologies were viral
hepatitis C (n = 4); viral hepatitis B + D (n = 2); alcoholic
(n = 4); or a combination of viral hepatitis B + C + alco-
holic (n = 1).
Detection of LIF receptor by immunohistochemistry Figure 7
Detection of LIF receptor by immunohistochemistry. 
(a): LIF-R expression in normal liver is observed in portal 
tracts (arrows) as well as along sinusoids (arrowheads); (b): 
Sinusoidal staining is highly increased in cirrhotic liver 
(arrows); (c) and (d): consecutive sections of a cirrhotic liver 
analyzed for LIF-R (c) or CD31 (d) expression. No labeling 
was seen when the antibodies were replaced by a species-
matched control antibody.Comparative Hepatology 2004, 3:10 http://www.comparative-hepatology.com/content/3/1/10
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Tissue sampling and processing
A portion of fresh tissue samples was routinely formalin-
fixed and paraffin-embedded for diagnosis and a portion
immediately frozen in liquid nitrogen-cooled isopentane
and stored at -80°C. Five µm-thick serial frozen sections
of each sample were air-dried on Super Frost/Plus slides
(Menzel Glaser, Germany) and processed for immunohis-
tochemistry. The procedures were in accordance with the
European guidelines for the use of human tissues.
Materials
Culture medium and additives, recombinant human epi-
dermal growth factor (EGF) and Moloney Murine Leuke-
mia Virus reverse transcriptase were from Gibco-BRL (Life
Technologies, Cergy-Pontoise, France). Taq polymerase
and the pGEM-Teasy plasmid were from Promega (Madi-
son, WI). The Qiagen RNeasy minikit was from Qiagen
(Courtaboeuf, France). The [α32P]dCTP, Hybond N+
membrane, ECL reagent, and the Ready-to-go DNA labe-
ling kit were from Amersham (Les Ulis, France). Ultrahyb
solution was from Ambion (Austin, TX). Recombinant
human IL-4 was a gift from Schering-Plough (Kenilworth,
NJ). Anti-gp130 mAb B-R3 was from Diaclone (Besançon,
France), anti-gp80 mAb M91 was from Coulter-Immu-
notech (Marseille, France), anti-phospho-STAT-3
(Tyr705) was from Cell Signaling Technology (Beverly,
MA). All other chemicals were from Sigma (St Quentin
Fallavier, France).
Cell culture
Human hepatic myofibroblasts were obtained from
explants of non-tumoral liver resected during partial
hepatectomy and characterized as previously described
[22,23]. Myofibroblasts were routinely grown in DMEM
containing 5% fetal calf serum, 5% pooled human AB
serum and 5 ng/ml EGF. For studies of LIF secretion, cells
were grown to confluence, made quiescent in serum and
EGF-free Waymouth medium for 2 days and then exposed
to agonists for 2 days. The results were normalized accord-
ing to the DNA content of the monolayer [24].
Detection of LIF in culture supernatants
ELISA
Human LIF was measured using an ELISA based on two
specific monoclonal antibodies, exactly as described
previously [25]. A standard curve was obtained with
recombinant glycosylated CHO-derived human LIF. The
detection limit of the assay is 20 pg/ml, and LIF can be
quantified at concentrations up to 1.2 ng/ml, without
sample dilution. This ELISA is not sensitive to soluble
receptor binding to the LIF molecule.
Biological assay
The Ba/F3 proliferation assays were performed, as
described previously [26], using the Ba/F3 gp190 + gp130
transfectant cell line which expresses the two human LIF
receptor chains (gp190 and gp130) and responds to all
cytokines sharing gp190. LIF-dependent Ba/F3 cells were
washed three times with RPMI to remove LIF which is
required to maintain the cell line; then, cells (5 × 103 per
well, in 50 µl, in duplicates) were incubated in the pres-
ence of 50 µl of three-fold dilutions of cytokines or super-
natant, as indicated. After three days at 37°C, 0.015 ml of
a 5 mg/ml solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (Sigma, Saint-Quentin Fal-
lavier, France), in PBS, was added to each well. After 4
hours at 37°C, 0.11 ml of a mixture of 95 % isopropanol
+ 5 % formic acid was added to the wells, and the absorb-
ance values were read at 570 nm, in a Titertek Multiskan
microplate reader (Labsystems, Les Ullis, France). The
blank consisted of eight wells containing the cells incu-
bated with the Ba/F3 culture medium without any added
cytokine.
Detection of LIF mRNA by Northern blot
Total RNA was isolated using the Qiagen RNeasy minikit.
For Northern blot, 2 µg RNA were separated on a 1.0%
agarose gel containing ethidium bromide in MOPS buffer.
Running buffer and gel contained 0.2 M formaldehyde.
The RNAs were transferred onto a Hybond N+ membrane
by downward capillary transfer in running buffer. Exami-
nation of the stained membrane under UV light was used
to confirm the quality of loading and transfer. The probe
used was a 730 bp cDNA containing the whole coding
sequence of human LIF [27]. Probes were labeled with
[α32P]dCTP, by random priming using the Ready-to-go
kit. Hybridization was performed using the Ultrahyb solu-
tion. The blots were washed in stringent conditions (0.1X
SSC, 0.1% SDS at 65°C).
RT-PCR and cloning
One µg of total RNA was reverse-transcribed using MMLV-
RT. An aliquot was used for PCR. Thirty five cycles were
performed, each consisting of 94°C, 30 s; 60°C, 30 s; and
72°C, 30 s. PCR was performed in 50 µl of a reaction
buffer containing 50 mM KCl, 10 mM Tris-HCl (pH 9.0),
1% Triton X-100, 1.5 mM MgCl2, 0.4 mM dNTPs, 0.2 mM
primers, and 1.25 units of Taq polymerase. Then, an aliq-
uot of the reaction was analyzed by agarose gel electro-
phoresis. The primers used are listed in Table 1 and are
also positioned on the LIF sequence in Figure 5. When
indicated, PCR products were directly cloned in the
pGEM-Teasy plasmid and sequenced on both strands
(Genome Express, Meylan, France).
Detection of LIF and LIF receptor expression
Antibodies and immunoperoxidase histochemistry
A commercially available polyclonal antibody against
human LIF (R&D Systems, Minneapolis, Minnesota,
USA), and different monoclonal antibodies againstComparative Hepatology 2004, 3:10 http://www.comparative-hepatology.com/content/3/1/10
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gp190, previously described [28], were used at concentra-
tions optimised on control tissues. For colocalization
experiments, mouse monoclonal antibodies against α-
smooth muscle actin (Dako A/S, Glostrup, Denmark),
and CD 31 (Dako) were used. For
immunohistochemistry, frozen sections were incubated
with the antibodies diluted in phosphate-buffered saline,
pH 7.4, containing 4% bovine serum albumin. After
washing, the epitopes were detected with the Envision+
system HRP detection and revealed with liquid diami-
nobenzidine (Dako). As negative control, we used either
a clarified mouse myeloma ascites (Cappel Research Prod-
ucts, Durham, USA) or a rabbit non-immune immu-
noglobulin fraction (Dako), at the same concentration as
the respective antibodies. Sections were examined with a
Zeiss Axioplan 2 microscope (Carl Zeiss Microscopy, Jena,
Germany). Images were acquired with an AxioCam cam-
era (Carl Zeiss Vision, Hallbergmoos, Germany) by means
of the AxioVision image processing and analysis system
(Carl Zeiss Vision).
Flow cytometry
For each staining, 2 × 105 cells were incubated for 30 min
at 4°C with saturating concentrations (10 µg/ml) of the
indicated antibody in 0.1 ml of PBS supplemented with 1
% bovine serum albumin (BSA) and 0.1 % human poly-
clonal IgG (w/v, both from Sigma). Then, cells were
washed twice with the same buffer and incubated for 30
min at 4°C with the FITC-conjugated goat anti-mouse
IgG. After washing with PBS, the cells were resuspended in
0.14 ml of PBS containing 1% formaldehyde (v/v) and
analysed by flow cytometry with a three color FACScalibur
flow cytometer (Becton-Dickinson, Mountain View, CA)
equipped with the CellQuest software. Control stainings
used the second antibody only.
ELISA (soluble receptor)
The sandwich ELISA assay for soluble gp190 measure-
ment has already been described [28]. It uses mAb 6G8 as
the capture mAb, and biotinylated 10B2 mAb as the trac-
ing mAb. Both mAb recognize distinct epitopes specific to
the ectodomain of gp190. The assay has a detection limit
of 0.5 ng/ml.
Immunodetection of phosphorylated STAT-3
Confluent cultures of myofibroblasts were left for 2 days
in serum-free medium, and subsequently exposed to
recombinant human LIF for 15 minutes [29]. Then, cells
were lyzed in modified RIPA buffer in the presence of pro-
tease and phosphatase inhibitors, as described [30]. Iden-
tical amounts of proteins were analyzed by Western blot
with an antibody against phospho-STAT-3. The blots were
stripped and rehybridized with an antibody against total
STAT-3.
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